Tolerability and effects of OROS® MPH (Concerta ®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non-interventional trial.

Attention deficit and hyperactivity disorders

Volumn 1, Issue 2, 2009, Pages 175-186

  Gerwe, Martin ^a   Stollhoff, Kirsten ^b   Mossakowski, Jacek ^b   Kuehle, Hans Juergen ^b   Goertz, Ulrich ^b   Schaefer, Christopher ^b   Bogdanow, Manuela ^b   Heger, Steffen ^b  

^a JANSSEN CILAG GMBH   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; METHYLPHENIDATE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; FAMILY; FEMALE; HUMAN; MALE; PEER GROUP; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; SOCIAL BEHAVIOR;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; FAMILY; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PEER GROUP; QUALITY OF LIFE; SOCIAL BEHAVIOR;

EID: 79960946177     PISSN: None     EISSN: 18666647     Source Type: Journal    
DOI: 10.1007/s12402-009-0010-6     Document Type: Article

References (0)